Senior Market Access Manager - Rare Disease

We are seeking a Senior Market Access Manager to lead Health Technology Appraisal (HTA) and Pricing engagements for selected rare disease assets and indications across the UK and Ireland. You will generate high‑quality national, regional and local access strategies, develop robust evidence submissions, and secure pricing business case approvals that unlock timely patient access to innovative therapies. This role sits at the heart of our rare disease portfolio, partnering across medical affairs, corporate affairs, commercial and global functions to shape and deliver access strategies that maximise asset value and impact for patients living with rare conditions.

What you’ll do

• HTA strategy and delivery (c.60%)
  • Lead the UK/I market access strategy for selected rare disease assets, collaborating across global and local teams.
  • Develop high‑quality HTA submissions and other national submissions, managing external suppliers as needed.
  • Own product‑level engagements with HTA bodies (NICE, SMC, AWMSG, NCPE), including scientific advice and system engagement meetings.
  • Serve as the UK subject‑matter expert on market access to inform optimal HTA strategies and pipeline commercialisation plans.
  • Contribute to lifecycle planning by shaping market access strategies that support launch and sustained uptake.
• Pricing strategy and process management (c.20%)
  • Lead UK/I pricing strategy for assigned rare disease assets and develop innovative pricing approaches suited to small populations and specialised commissioning.
  • Build and secure internal pricing business cases; manage inputs to commercial access agreements (e.g., PAS, tenders).
  • Collaborate with New Product Planning to maintain accurate UK Pharmascan entries for pipeline products.
• External engagement and advocacy (c.20%)
  • Act as a subject‑matter expert on national and regional access and funding pathways.
  • Engage national, regional and local stakeholders to improve the access environment in partnership with Corporate Affairs.
  • Represent the organisation at relevant conferences (e.g., NICE Conference, ISPOR) to gather insights and anticipate opportunities.
  • Translate national decisions into local context by communicating evolving system dynamics and implications for access.

Essential qualifications

• Bachelor’s degree in Life Science or closely related discipline.
• Formal training or demonstrated proficiency in HTA and UK market access frameworks (NICE, SMC, AWMSG, NCPE).
• Strong understanding of specialised/highly specialised commissioning in the UK (NHSE) and orphan/ultra‑orphan access pathways.

Essential experience

• Experience leading and delivering successful HTA submissions for rare disease therapies.
• Proven track record developing and executing pricing and access strategies, securing internal pricing approvals, and managing commercial access agreements (e.g., PAS).
• Strong external engagement with national agencies and payers; effective participation in advice meetings, consultations and system forums.
• Leadership of HTA submissions (NICE/SMC/AWMSG/NCPE), including co‑leading evidence generation with health economists and managing external suppliers, with successful outcomes for high‑cost, specialised/rare/orphan assets.
• Experience partnering with specialised centres, clinical networks and patient organisations to inform access strategy and evidence positioning.
• Exceptional project management, delivering cross‑functional submissions and launch‑critical milestones on time.
• Fluent English with excellent written and verbal communication across technical and executive audiences.

Skills and capabilities

• Strategic mindset and technical depth: designs optimal HTA and pricing/access pathways; understands funding flows and stakeholder dynamics across UK & Ireland in the context of rare diseases.
• Results orientation and accountability: delivers complex submissions and pricing approvals to plan; sets and manages clear KPIs.
• External influence and network building: credible engagement with HTA bodies, payers and policy stakeholders to enable timely, positive decisions.
• Communication excellence: synthesises complex evidence and policy into clear recommendations; produces high‑quality submission content and executive briefs.
• Rare disease acumen: articulates compelling value propositions, addresses small‑population evidence challenges (heterogeneity, RWE), and navigates specialised commissioning.
• Cross‑functional leadership: orchestrates multi‑disciplinary teams, resolves ambiguity and drives clarity in a matrix.
• Integrity and judgement: applies governance rigour and risk management across HTA, pricing and external engagements.

Desirable strengths

• Negotiation and commercial acumen; analytical fluency with models and RWE; future scanning of HTA and policy; familiarity with international orphan frameworks; AI literacy to streamline HTA and submission processes.

Interested? Please submit your CV by COB 7th April 2026.

Date Posted 18-Mar-2026 Closing Date 06-Apr-2026

Our mission is to build an inclusive and equitable environment. We want people to feel they belong at AstraZeneca and Alexion, starting with our recruitment process. We welcome and consider applications from all qualified candidates, regardless of characteristics. We offer reasonable adjustments/accommodations to help all candidates to perform at their best. If you have a need for any adjustments/accommodations, please complete the section in the application form.